A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Combivir Patient, Information, Instructions - Lamivudine and zidovudine
Combivir Patient, Information, Instructions - Lamivudine and zidovudine
PATIENT INFORMATION
COMBIVIR is not a cure for HIV infection and patients may continue
to experience illnesses associated with HIV infection, including opportunistic
infections. Patients should be advised that the use of COMBIVIR has not been
shown to reduce the risk of transmission of HIV to others through sexual contact
or blood contamination. Patients should be informed that the major toxicities
of COMBIVIR are neutropenia and/or anemia. They should be told of the extreme
importance of having their blood counts followed closely while on therapy, especially
for patients with advanced HIV disease. Patients should be advised of the importance
of taking COMBIVIR as it is prescribed.
Patients should be informed that redistribution or accumulation
of body fat may occur in patients receiving antiretroviral therapy and that
the cause and long-term health effects of these conditions are not known at
this time.
Patients co-infected with HIV and HBV should be informed
that deterioration of liver disease has occurred in some cases when
treatment with lamivudine was discontinued. Patients should be advised to
discuss any changes in regimen with their physician.
Please also refer to the WARNINGS
and PRECAUTIONS sections.
top
